Klin Farmakol Farm. 2016;30(2):9-15 | DOI: 10.36290/far.2016.013

Therapeutic monitoring of antiepileptic drugs, part I - general principles, “old” antiepileptics

Milan Grundmann1, Ivana Kacířová1,2
1 Ústav klinické farmakologie, Lékařská fakulta, Ostravská univerzita, Ostrava
2 Oddělení klinické farmakologie, Ústav laboratorní diagnostiky, Fakultní nemocnice Ostrava

Therapeutic drug concentration monitoring has been used as a tool to optimize treatment of epilepsy for almost 60 years. The concept

of the method rests on the assumption that clinical effects correlate better with drug concentrations than with the dose. It seeks

to optimize the seizure suppressing effects of antiepileptic drugs while minimizing their adverse effects by managing their medication

regimen with the assistance of information on the concentration of antiepileptic drugs in the serum, plasma or saliva. For

most antiepileptic drugs, “reference ranges” have been reported which define the serum concentrations at which most patients are

expected to exhibit an optimal clinical response. Due to individual variation, however, many patients may require concentrations

outside the reference ranges. In many situations, patient management is best guided by determination of the “individual therapeutic

concentration,” defined as the concentration at which an individual has been found to achieve seizure freedom with good tolerability,

or the best compromise between improvement in seizure control and concentration-related adverse effects.

Keywords: therapeutic drug concentration monitoring, antiepileptic drugs, reference ranges

Published: September 19, 2016  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Grundmann M, Kacířová I. Therapeutic monitoring of antiepileptic drugs, part I - general principles, “old” antiepileptics. Klin Farmakol Farm. 2016;30(2):9-15. doi: 10.36290/far.2016.013.
Download citation

References

  1. Buchthal F, Svensmark O. Aspects of the pharmacology of phenytoin (dilantin) and phenobarbital relevant to their dosage in the treatment of epilepsy. Epilepsia 1960; 1: 373-384. Go to original source... Go to PubMed...
  2. Patsalos PN, Berry DJ, Bourgeois BF, et al. Antiepileptic drugs-best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia 2008; 49(7): 1239-1276. Go to original source... Go to PubMed...
  3. Perucca E. Free level monitoring of antiepileptic drugs. Clinical usefulness and case studies. Clin Pharmacokinet 1984; 9(Suppl. 1): 71-78. Go to original source... Go to PubMed...
  4. Pippenger CE, Penry JK, Kutt H. Antiepileptic drugs: quantitative analysis and interpretation. New York, PA: Raven Press, 1978.
  5. Tsanaclis LM, Wilson JF. Comparison by external quality assessment of performance of analytical systems for measurement of therapeutic drugs in serum. Ther Drug Monit 1997; 19(4): 420-426. Go to original source... Go to PubMed...
  6. Williams J, Bialer M, Johannessen SI, et al. Interlaboratory variability in the quantification of new generation antiepileptic drugs based on external quality assessment data. Epilepsia 2003; 44(1): 40-45. Go to original source... Go to PubMed...
  7. Patsalos PN, Berry DJ. Therapeutic drug monitoring of antiepileptic drugs by use of saliva. Ther Drug Monit 2013; 35(1): 4-29. Go to original source... Go to PubMed...
  8. Patsalos PN. Antiepileptic drug interactions. A clinical Guide. 2nd ed. London, PA: Springer-Verlag, 2013: 437. Go to original source...
  9. Krasowski MD, McMillin GA. Advances in anti-epileptic drug testing. Clin Chim Acta 2014; 436: 224-236. Go to original source... Go to PubMed...
  10. Milosheska D, Grabnar I, Vovk T. Dried blood spots for monitoring and individualization of antiepileptic drug treatment. Eur J Pharm Sci 2015; 75: 25-39. Go to original source... Go to PubMed...
  11. www.sukl.cz.
  12. Kacirova I, Grundmann M, Silhan P, Brozmanova H. A Case Report of Clonazepam Dependence: Utilization of Therapeutic Drug Monitoring During Withdrawal Period. Medicine (Baltimore) 2016; 95(9): e2881. Go to original source... Go to PubMed...




Clinical Pharmacology and Pharmacy

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.